Pub. Date : 2021 Jan
PMID : 33236159
5 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports. | olaparib | tumor protein p53 | Homo sapiens |
| 2 | Exome analyses following olaparib treatment identified de novo TP53 mutations, as well as increased frequencies of pre-existing TP53 mutations compared with the primary tumor. | olaparib | tumor protein p53 | Homo sapiens |
| 3 | Exome analyses following olaparib treatment identified de novo TP53 mutations, as well as increased frequencies of pre-existing TP53 mutations compared with the primary tumor. | olaparib | tumor protein p53 | Homo sapiens |
| 4 | In HCT116 TP53-/- cells carrying BRCA2 pathogenic mutations, TP53 inactivating mutations were associated with lower sensitivity to olaparib in vitro. | olaparib | tumor protein p53 | Homo sapiens |
| 5 | Thus, inactivating TP53 mutations may be associated to olaparib resistance in the presence of BRCA mutations. | olaparib | tumor protein p53 | Homo sapiens |